Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
27
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner | 3 | $972.8K | $0 | 2024-05-14 |
| Golipour Azadeh | Chief Technology Officer | 7 | $0 | $0 | 2024-02-05 |
| Ridha Essra | Chief Medical Officer | 8 | $0 | $0 | 2024-02-05 |
| Ostrowski Erik | Interim CEO, President and CFO | 13 | $0 | $0 | 2024-02-05 |
| Avruch Steven | VP & General Counsel | 11 | $0 | $0 | 2024-02-05 |
| PAIGE CHRISTOPHER | Director | 12 | $0 | $907.2K | 2023-06-06 |
| Jenkins Annalisa | Director | 6 | $0 | $0 | 2023-06-06 |
| Vickers Philip J. | Director | 8 | $40.1K | $0 | 2023-06-06 |
| Farfel Gail M | Director | 5 | $0 | $0 | 2023-06-06 |
| Booth Bruce | Director | 13 | $15.00M | $0 | 2023-06-06 |
| CLARK IAN T | Director | 6 | $0 | $0 | 2023-06-06 |
| Donenberg Phillip B. | Director | 8 | $23.4K | $0 | 2023-06-06 |
| MACKAY GEOFFREY | See Remarks | 21 | $0 | $2.16M | 2023-02-08 |
| Petersen Deanna M | Chief Business Officer | 7 | $0 | $0 | 2023-02-08 |
| Mason Christopher | Chief Scientific Officer | 1 | $0 | $0 | 2021-06-10 |
| Escolar Diana | Chief Medical Officer | 2 | $0 | $0 | 2021-06-10 |
| Volck Birgitte | President of R&D | 2 | $0 | $0 | 2020-03-04 |
| ATLAS VENTURE ASSOCIATES X, L.P. | 10% Owner | 1 | $0 | $0 | 2020-02-13 |
| Atlas Venture Fund X, L.P. | 10% Owner | 1 | $15.00M | $0 | 2019-07-19 |
| Clarus Ventures III GP, L.P. | 10% Owner | 1 | $0 | $0 | 2019-05-20 |
| SV Life Sciences Fund VI, L.P. | 10% Owner | 2 | $0 | $0 | 2019-01-16 |
| KREHER NERISSA | Chief Medical Officer | 2 | $0 | $0 | 2018-10-08 |
| Dorton Katina | Chief Financial Officer | 2 | $0 | $0 | 2018-10-08 |
| Atlas Venture Associates X, LLC | 10% Owner | 6 | $0 | $0 | 2018-06-25 |
| SV Life Sciences Fund VI Strategic Partners, L.P. | 10% Owner | 8 | $0 | $0 | 2018-06-25 |
| Requadt Scott | Director | 4 | $0 | $0 | 2018-06-25 |
| Clarus Lifesciences III, L.P. | 10% Owner | 4 | $0 | $0 | 2018-06-25 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner | P Buy | 2024-05-14 | 2024-05-15 | 296,882 | $1.30 | $385.9K | 4,768,262 | SEC↗ |
| Leonard Braden Michael | 10% Owner | P Buy | 2024-05-13 | 2024-05-15 | 216,053 | $1.26 | $272.2K | 4,471,380 | SEC↗ |
| Leonard Braden Michael | 10% Owner | P Buy | 2024-05-13 | 2024-05-15 | 253,700 | $1.24 | $314.6K | 4,255,327 | SEC↗ |
| Avruch Steven | Chief Legal Officer | F Tax w/h | 2024-02-05 | 2024-02-05 | 10,812 | $1.20 | $13.0K | 22,022 | SEC↗ |
| Ostrowski Erik | Interim CEO, President and C | F Tax w/h | 2024-02-05 | 2024-02-05 | 13,099 | $1.20 | $15.7K | 29,285 | SEC↗ |
| Ridha Essra | Chief Medical Officer | F Tax w/h | 2024-02-05 | 2024-02-05 | 16,953 | $1.20 | $20.3K | 15,881 | SEC↗ |
| Golipour Azadeh | Chief Technology Officer | F Tax w/h | 2024-02-05 | 2024-02-05 | 12,232 | $1.20 | $14.7K | 55,872 | SEC↗ |
| Avruch Steven | Chief Legal Officer | M Exercise deriv | 2024-02-01 | 2024-02-05 | 32,834 | — | $0 | 98,499 | SEC↗ |
| Ostrowski Erik | Interim CEO, President and C | M Exercise deriv | 2024-02-01 | 2024-02-05 | 40,084 | — | $0 | 120,249 | SEC↗ |
| Ridha Essra | Chief Medical Officer | M Exercise deriv | 2024-02-01 | 2024-02-05 | 32,834 | — | $0 | 98,499 | SEC↗ |
| Golipour Azadeh | Chief Technology Officer | M Exercise deriv | 2024-02-01 | 2024-02-05 | 37,334 | — | $0 | 111,999 | SEC↗ |
| Avruch Steven | Chief Legal Officer | M Exercise | 2024-02-01 | 2024-02-05 | 32,834 | — | $0 | 32,834 | SEC↗ |
| Ostrowski Erik | Interim CEO, President and C | M Exercise | 2024-02-01 | 2024-02-05 | 40,084 | — | $0 | 42,384 | SEC↗ |
| Ridha Essra | Chief Medical Officer | M Exercise | 2024-02-01 | 2024-02-05 | 32,834 | — | $0 | 32,834 | SEC↗ |
| Golipour Azadeh | Chief Technology Officer | M Exercise | 2024-02-01 | 2024-02-05 | 37,334 | — | $0 | 68,104 | SEC↗ |
| Ostrowski Erik | Interim CEO, President and C | A Award deriv | 2023-07-01 | 2023-07-03 | 70,000 | — | $0 | 70,000 | SEC↗ |
| Golipour Azadeh | Chief Technology Officer | F Tax w/h | 2023-06-12 | 2023-06-13 | 111 | $1.21 | $134 | 30,770 | SEC↗ |
| Golipour Azadeh | Chief Technology Officer | F Tax w/h | 2023-06-12 | 2023-06-13 | 5,463 | $1.19 | $6.5K | 30,881 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2023-06-06 | 2023-06-08 | 17,643 | — | $0 | 17,643 | SEC↗ |
| Jenkins Annalisa | Director | A Award deriv | 2023-06-06 | 2023-06-08 | 17,643 | — | $0 | 17,643 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2023-06-06 | 2023-06-08 | 17,643 | — | $0 | 17,643 | SEC↗ |
| Farfel Gail M | Director | A Award deriv | 2023-06-06 | 2023-06-08 | 17,643 | — | $0 | 17,643 | SEC↗ |
| Vickers Philip J. | Director | A Award deriv | 2023-06-06 | 2023-06-08 | 17,643 | — | $0 | 17,643 | SEC↗ |
| Donenberg Phillip B. | Director | A Award deriv | 2023-06-06 | 2023-06-08 | 17,643 | — | $0 | 17,643 | SEC↗ |
| PAIGE CHRISTOPHER | Director | A Award deriv | 2023-06-06 | 2023-06-08 | 17,643 | — | $0 | 17,643 | SEC↗ |
| Avruch Steven | Chief Legal Officer | A Award deriv | 2023-02-08 | 2023-02-10 | 131,333 | — | $0 | 131,333 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | A Award deriv | 2023-02-08 | 2023-02-10 | 300,667 | — | $0 | 300,667 | SEC↗ |
| Golipour Azadeh | Chief Technology Officer | A Award deriv | 2023-02-08 | 2023-02-10 | 149,333 | — | $0 | 149,333 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award deriv | 2023-02-08 | 2023-02-10 | 160,333 | — | $0 | 160,333 | SEC↗ |
| Ridha Essra | Chief Medical Officer | A Award deriv | 2023-02-08 | 2023-02-10 | 131,333 | — | $0 | 131,333 | SEC↗ |
| Petersen Deanna M | Chief Business Officer | A Award deriv | 2023-02-08 | 2023-02-10 | 86,667 | — | $0 | 86,667 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | M Exercise deriv | 2023-01-24 | 2023-01-26 | 45,999 | — | $0 | 0 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | M Exercise | 2023-01-24 | 2023-01-26 | 45,999 | $0.91 | $41.9K | 188,012 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | G Gift | 2022-12-28 | 2023-01-26 | 245,123 | — | $0 | 445,123 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | G Gift | 2022-12-28 | 2023-01-26 | 245,123 | — | $0 | 142,013 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | M Exercise deriv | 2022-12-23 | 2022-12-28 | 142,013 | — | $0 | 0 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | M Exercise | 2022-12-23 | 2022-12-28 | 142,013 | $0.41 | $58.2K | 387,136 | SEC↗ |
| Avruch Steven | Chief Legal Officer | A Award deriv | 2022-12-08 | 2022-12-09 | 169,500 | — | $0 | 169,500 | SEC↗ |
| Golipour Azadeh | Chief Technology Officer | A Award deriv | 2022-12-08 | 2022-12-09 | 165,000 | — | $0 | 165,000 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award deriv | 2022-12-08 | 2022-12-09 | 221,000 | — | $0 | 221,000 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | A Award deriv | 2022-12-08 | 2022-12-09 | 388,000 | — | $0 | 388,000 | SEC↗ |
| Petersen Deanna M | Chief Business Officer | A Award deriv | 2022-12-08 | 2022-12-09 | 111,500 | — | $0 | 111,500 | SEC↗ |
| Ridha Essra | Chief Medical Officer | A Award deriv | 2022-12-08 | 2022-12-09 | 183,000 | — | $0 | 183,000 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Jenkins Annalisa | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Jenkins Annalisa | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Farfel Gail M | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Farfel Gail M | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Vickers Philip J. | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Vickers Philip J. | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Donenberg Phillip B. | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Donenberg Phillip B. | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| PAIGE CHRISTOPHER | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| PAIGE CHRISTOPHER | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 17,478 | — | $0 | 17,478 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 145,000 | — | $0 | 145,000 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 170,000 | — | $0 | 170,000 | SEC↗ |
| Avruch Steven | Chief Legal Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Avruch Steven | Chief Legal Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Ridha Essra | Chief Medical Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Ridha Essra | Chief Medical Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 80,000 | — | $0 | 80,000 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | A Award deriv | 2022-02-02 | 2022-02-04 | 328,500 | — | $0 | 328,500 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | A Award deriv | 2022-02-02 | 2022-02-04 | 405,000 | — | $0 | 405,000 | SEC↗ |
| Petersen Deanna M | Chief Business Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Petersen Deanna M | Chief Business Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Ridha Essra | Chief Medical Officer | A Award deriv | 2021-11-01 | 2021-11-02 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Vickers Philip J. | Director | P Buy | 2021-07-07 | 2021-07-08 | 4,800 | $8.35 | $40.1K | 4,800 | SEC↗ |
| Donenberg Phillip B. | Director | A Award deriv | 2021-06-10 | 2021-06-14 | 17,438 | — | $0 | 17,438 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2021-06-10 | 2021-06-14 | 17,438 | — | $0 | 17,438 | SEC↗ |
| PAIGE CHRISTOPHER | Director | A Award deriv | 2021-06-10 | 2021-06-14 | 17,438 | — | $0 | 17,438 | SEC↗ |
| Jenkins Annalisa | Director | A Award deriv | 2021-06-10 | 2021-06-14 | 17,438 | — | $0 | 17,438 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2021-06-10 | 2021-06-14 | 17,438 | — | $0 | 17,438 | SEC↗ |
| Farfel Gail M | Director | A Award deriv | 2021-06-10 | 2021-06-14 | 17,438 | — | $0 | 17,438 | SEC↗ |
| Vickers Philip J. | Director | A Award deriv | 2021-06-10 | 2021-06-14 | 17,438 | — | $0 | 17,438 | SEC↗ |
| Avruch Steven | Chief Legal Officer | A Award deriv | 2021-06-10 | 2021-06-14 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Escolar Diana | Chief Medical Officer | A Award deriv | 2021-06-10 | 2021-06-14 | 50,000 | — | $0 | 50,000 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | A Award deriv | 2021-06-10 | 2021-06-14 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award deriv | 2021-06-10 | 2021-06-14 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Mason Christopher | Chief Scientific Officer | A Award deriv | 2021-06-10 | 2021-06-14 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Petersen Deanna M | Chief Business Officer | A Award deriv | 2021-06-10 | 2021-06-14 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Donenberg Phillip B. | Director | P Buy | 2021-02-17 | 2021-02-18 | 2,000 | $11.71 | $23.4K | 2,000 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award deriv | 2021-02-04 | 2021-02-04 | 119,100 | — | $0 | 119,100 | SEC↗ |
| Petersen Deanna M | Chief Business Officer | A Award deriv | 2021-02-04 | 2021-02-04 | 86,600 | — | $0 | 86,600 | SEC↗ |
| Avruch Steven | Chief Legal Officer | A Award deriv | 2021-02-04 | 2021-02-04 | 98,200 | — | $0 | 98,200 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | A Award deriv | 2021-02-04 | 2021-02-04 | 343,850 | — | $0 | 343,850 | SEC↗ |
| Escolar Diana | Chief Medical Officer | A Award deriv | 2021-02-01 | 2021-02-02 | 130,000 | — | $0 | 130,000 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | M Exercise deriv | 2020-12-24 | 2020-12-28 | 100,000 | — | $0 | 142,013 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | M Exercise | 2020-12-24 | 2020-12-28 | 100,000 | $0.41 | $41.0K | 245,123 | SEC↗ |
| Farfel Gail M | Director | A Award deriv | 2020-10-19 | 2020-10-21 | 28,000 | — | $0 | 28,000 | SEC↗ |
| PAIGE CHRISTOPHER | Director | A Award deriv | 2020-06-04 | 2020-06-05 | 14,000 | — | $0 | 14,000 | SEC↗ |
| Vickers Philip J. | Director | A Award deriv | 2020-06-04 | 2020-06-05 | 14,000 | — | $0 | 14,000 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2020-06-04 | 2020-06-05 | 14,000 | — | $0 | 14,000 | SEC↗ |
| Jenkins Annalisa | Director | A Award deriv | 2020-06-04 | 2020-06-05 | 14,000 | — | $0 | 14,000 | SEC↗ |
| Donenberg Phillip B. | Director | A Award deriv | 2020-06-04 | 2020-06-05 | 14,000 | — | $0 | 14,000 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2020-06-04 | 2020-06-05 | 14,000 | — | $0 | 14,000 | SEC↗ |
| Avruch Steven | Chief Legal Officer | A Award deriv | 2020-03-04 | 2020-03-06 | 90,000 | — | $0 | 90,000 | SEC↗ |
| MACKAY GEOFFREY | President & CEO | A Award deriv | 2020-03-04 | 2020-03-06 | 292,300 | — | $0 | 292,300 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award deriv | 2020-03-04 | 2020-03-06 | 100,900 | — | $0 | 100,900 | SEC↗ |
| Volck Birgitte | President of R&D | A Award deriv | 2020-03-04 | 2020-03-06 | 76,000 | — | $0 | 76,000 | SEC↗ |
| Petersen Deanna M | Chief Business Officer | A Award deriv | 2020-03-04 | 2020-03-06 | 90,000 | — | $0 | 90,000 | SEC↗ |
| ATLAS VENTURE ASSOCIATES X, L. | 10% Owner | J Other | 2020-02-13 | 2020-02-18 | 1,046,426 | — | $0 | 3,710,052 | SEC↗ |
| MACKAY GEOFFREY | See Remarks | S Sale | 2020-02-12 | 2020-02-14 | 1,400 | $29.07 | $40.7K | 345,123 | SEC↗ |
| MACKAY GEOFFREY | See Remarks | S Sale | 2020-02-11 | 2020-02-11 | 18,404 | $28.10 | $517.2K | 346,523 | SEC↗ |
| MACKAY GEOFFREY | See Remarks | S Sale | 2020-02-11 | 2020-02-11 | 44,596 | $27.36 | $1.22M | 364,927 | SEC↗ |
| PAIGE CHRISTOPHER | Director | S Sale | 2020-02-11 | 2020-02-11 | 15,000 | $28.00 | $420.0K | 252,512 | SEC↗ |
| PAIGE CHRISTOPHER | Director | S Sale | 2020-01-28 | 2020-01-30 | 10,000 | $23.00 | $230.0K | 267,512 | SEC↗ |
| Booth Bruce | Director | P Buy | 2019-07-19 | 2019-07-23 | 810,811 | $18.50 | $15.00M | 5,567,289 | SEC↗ |
| Atlas Venture Fund X, L.P. | 10% Owner | P Buy | 2019-07-19 | 2019-07-23 | 810,811 | $18.50 | $15.00M | 5,567,289 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2019-06-11 | 2019-06-13 | 9,675 | — | $0 | 9,675 | SEC↗ |
| Donenberg Phillip B. | Director | A Award deriv | 2019-06-11 | 2019-06-13 | 9,675 | — | $0 | 9,675 | SEC↗ |
| Jenkins Annalisa | Director | A Award deriv | 2019-06-11 | 2019-06-13 | 9,675 | — | $0 | 9,675 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2019-06-11 | 2019-06-13 | 9,675 | — | $0 | 9,675 | SEC↗ |
| PAIGE CHRISTOPHER | Director | A Award deriv | 2019-06-11 | 2019-06-13 | 9,675 | — | $0 | 9,675 | SEC↗ |
| Vickers Philip J. | Director | A Award deriv | 2019-06-11 | 2019-06-13 | 9,675 | — | $0 | 9,675 | SEC↗ |
| Clarus Ventures III GP, L.P. | 10% Owner | J Other | 2019-05-20 | 2019-05-22 | 1,481,163 | — | $0 | 1,481,162 | SEC↗ |
| MACKAY GEOFFREY | See Remarks | S Sale | 2019-04-08 | 2019-04-09 | 698 | $27.07 | $18.9K | 409,523 | SEC↗ |
| PAIGE CHRISTOPHER | Director | S Sale | 2019-04-08 | 2019-04-09 | 100 | $26.92 | $2.7K | 277,512 | SEC↗ |
| PAIGE CHRISTOPHER | Director | S Sale | 2019-04-08 | 2019-04-09 | 2,400 | $25.84 | $62.0K | 277,612 | SEC↗ |
| MACKAY GEOFFREY | See Remarks | S Sale | 2019-04-05 | 2019-04-09 | 13,302 | $27.26 | $362.6K | 410,221 | SEC↗ |
| PAIGE CHRISTOPHER | Director | S Sale | 2019-04-05 | 2019-04-09 | 867 | $26.21 | $22.7K | 280,012 | SEC↗ |
| PAIGE CHRISTOPHER | Director | S Sale | 2019-04-05 | 2019-04-09 | 6,633 | $25.59 | $169.7K | 280,879 | SEC↗ |
| MACKAY GEOFFREY | See Remarks | A Award deriv | 2019-03-05 | 2019-03-07 | 100,000 | — | $0 | 100,000 | SEC↗ |
| SV Life Sciences Fund VI, L.P. | 10% Owner | J Other | 2019-01-16 | 2019-01-18 | 26,660 | — | $0 | 63,913 | SEC↗ |
| SV Life Sciences Fund VI, L.P. | 10% Owner | J Other | 2019-01-16 | 2019-01-18 | 778,663 | — | $0 | 1,866,791 | SEC↗ |
| Vickers Philip J. | Director | A Award deriv | 2019-01-07 | 2019-01-09 | 18,743 | — | $0 | 18,743 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award deriv | 2019-01-02 | 2019-01-04 | 186,000 | — | $0 | 186,000 | SEC↗ |
| Avruch Steven | VP & General Counsel | A Award deriv | 2019-01-02 | 2019-01-04 | 88,636 | — | $0 | 88,636 | SEC↗ |
| Ostrowski Erik | Chief Financial Officer | A Award | 2019-01-02 | 2019-01-04 | 2,300 | — | $0 | 2,300 | SEC↗ |
| Volck Birgitte | President of R&D | A Award deriv | 2018-12-17 | 2018-12-19 | 293,000 | — | $0 | 293,000 | SEC↗ |
| KREHER NERISSA | Chief Medical Officer | M Exercise deriv | 2018-10-08 | 2018-10-10 | 2,942 | — | $0 | 24,629 | SEC↗ |
| Dorton Katina | Chief Financial Officer | M Exercise deriv | 2018-10-08 | 2018-10-10 | 10,000 | — | $0 | 148,318 | SEC↗ |
| KREHER NERISSA | Chief Medical Officer | M Exercise | 2018-10-08 | 2018-10-10 | 2,942 | $0.91 | $2.7K | 2,942 | SEC↗ |
| Dorton Katina | Chief Financial Officer | M Exercise | 2018-10-08 | 2018-10-10 | 10,000 | $0.91 | $9.1K | 10,000 | SEC↗ |
| Booth Bruce | Director | C Conversion deriv | 2018-06-25 | 2018-06-25 | 3,740,239 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | C Conversion deriv | 2018-06-25 | 2018-06-25 | 12,580,199 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | C Conversion deriv | 2018-06-25 | 2018-06-25 | 3,333,333 | — | $0 | 0 | SEC↗ |
| Clarus Lifesciences III, L.P. | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 9,435,150 | — | $0 | 0 | SEC↗ |
| Clarus Lifesciences III, L.P. | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 2,805,179 | — | $0 | 0 | SEC↗ |
| SV Life Sciences Fund VI Strat | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 9,122,809 | — | $0 | 0 | SEC↗ |
| SV Life Sciences Fund VI Strat | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 312,341 | — | $0 | 0 | SEC↗ |
| SV Life Sciences Fund VI Strat | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 1,808,211 | — | $0 | 0 | SEC↗ |
| SV Life Sciences Fund VI Strat | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 61,908 | — | $0 | 0 | SEC↗ |
| Requadt Scott | Director | C Conversion deriv | 2018-06-25 | 2018-06-25 | 2,805,179 | — | $0 | 0 | SEC↗ |
| Requadt Scott | Director | C Conversion deriv | 2018-06-25 | 2018-06-25 | 9,435,150 | — | $0 | 0 | SEC↗ |
| Atlas Venture Associates X, LL | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 12,580,199 | — | $0 | 0 | SEC↗ |
| Atlas Venture Associates X, LL | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 3,740,239 | — | $0 | 0 | SEC↗ |
| Atlas Venture Associates X, LL | 10% Owner | C Conversion deriv | 2018-06-25 | 2018-06-25 | 3,333,333 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | C Conversion | 2018-06-25 | 2018-06-25 | 806,711 | — | $0 | 806,711 | SEC↗ |
| Booth Bruce | Director | C Conversion | 2018-06-25 | 2018-06-25 | 3,044,579 | — | $0 | 3,851,290 | SEC↗ |
| Booth Bruce | Director | C Conversion | 2018-06-25 | 2018-06-25 | 905,188 | — | $0 | 4,756,478 | SEC↗ |
| Clarus Lifesciences III, L.P. | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 2,283,434 | — | $0 | 2,283,434 | SEC↗ |
| Clarus Lifesciences III, L.P. | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 678,891 | — | $0 | 2,962,325 | SEC↗ |
| SV Life Sciences Fund VI Strat | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 14,982 | — | $0 | 90,573 | SEC↗ |
| SV Life Sciences Fund VI Strat | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 75,591 | — | $0 | 75,591 | SEC↗ |
| SV Life Sciences Fund VI Strat | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 437,611 | — | $0 | 2,645,454 | SEC↗ |
| SV Life Sciences Fund VI Strat | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 2,207,843 | — | $0 | 2,207,843 | SEC↗ |
| Requadt Scott | Director | C Conversion | 2018-06-25 | 2018-06-25 | 678,891 | — | $0 | 2,962,325 | SEC↗ |
| Requadt Scott | Director | C Conversion | 2018-06-25 | 2018-06-25 | 2,283,434 | — | $0 | 2,283,434 | SEC↗ |
| Atlas Venture Associates X, LL | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 905,188 | — | $0 | 4,756,478 | SEC↗ |
| Atlas Venture Associates X, LL | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 3,044,579 | — | $0 | 3,851,290 | SEC↗ |
| Atlas Venture Associates X, LL | 10% Owner | C Conversion | 2018-06-25 | 2018-06-25 | 806,711 | — | $0 | 806,711 | SEC↗ |
| Donenberg Phillip B. | Director | A Award deriv | 2018-06-20 | 2018-06-22 | 18,743 | — | $0 | 18,743 | SEC↗ |